Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 743-753

  Zamboni, William C ^a   Stewart, Clinton F ^a,b   Cheshire, Pamela J ^a   Richmond, Lois B ^a   Hanna, Suzan K ^a   Luo, Xialolong ^a   Poquette, Catherine ^a   McGovren, J Patrick ^c   Houghton, Janet A ^a   Houghton, Peter J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; LACTONE DERIVATIVE; TOPOTECAN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DIVISION; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED CBA; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; THYMECTOMY; TRANSPLANTATION, HETEROLOGOUS;

EID: 15444357985     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Rivory, L. P., Bowies, M. R., Robert, J., and Pond, S. M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) by human liver carboxylesterase. Biochem. Pharmacol., 52: 1103-1111, 1996.
2. Satoh, R., Hosokawa, M., Atsumi, R., Suzuki, W., Hakusui, H., and Nagai, E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy camptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull., 17: 662-664, 1994.
3. Kunimoto, T., Nitta, K., Tanka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-( 1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944-5947, 1987.
4. Matsuzaki, T., Yokokura, T., Mutai, M., and Tsuruo, T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol., 21: 308-312, 1988.
5. Bissery, M. C., Mathieu-Boue, A., and Lavelle, F. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. Annu. Meet. Am. Assoc. Cancer Res., 32: A2389, 1991.
6. Bissery, M. C., Vrignaud, P., Lavelle, F., and Chabot, G. G. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs, 7: 437-460, 1996.
7. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192-198, 1991.
8. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
9. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21: 71-74, 1988.
10. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992.
11. Fujita, A., Takabatake, H., Tagaki, S., and Sekine, K. Pilot study of irinotecan in refractory small cell lung cancer (in Japanese). Gan. To. Kagaku. Ryoho., 22: 889-893, 1995.
12. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., and Oguro, M. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
13. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., and Masuda, N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
14. Fukuoka, M., and Masuda, N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother. Pharmacol., 34 (Suppl.): S105-S111, 1994.
15. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol., 11: 909-913, 1993.
16. Nishimura, G., Satou, T., Yoshimitsu, Y., Kurosaka, Y., Fujimura, T., Sugiyama, K., Kanno, M., Yonemura, Y., Miwa, K., and Miyazaki, I. Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer (in Japanese). Gan. To. Kagaku. Ryoho., 22: 93-97, 1995.
17. Rougier, P., Culine, S., Bugat, R., Brunet, P., Douillard, J. Y., Ychou, M., Marty, M., Bonneterre, J., Ganem, G., Seitz, J. F., Negrier, S., Namer, M., Conroy, T., Burki, F., Shearrer, A., Droz, J. P., Mathiue-Boué, A., Mahjoubi, M., and Herait, P. Multicentric Phase II study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRC): preliminary results. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 13: A585, 1994.
18. Rothenberg, M. L., Eckardt, J. R., Burris, H. A., Nelson, J., Kuhn, J. G., Chen, S. F., Hilsenbeck, S. G., Clark, G. M., Fields, S. M., and Rodriguez, G. I. Irinotecan (CPT-11) as second-line therapy for patients with 5-FU-refractory colorectal cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 13: A578, 1994.
19. Pilot, H. C., Wender, D., O'Connell, M. J., Wieand, H. S., and Mailliard, J. A. A Phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 13: A573, 1994.
20. Burris, H. A., Rothenberg, M. L., Kuhn, J. G., and Von Hoff, D. D. Clinical trials with the topoisomerase I inhibitors. Semin. Oncol., 19: 663-669, 1992.
21. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Yokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
22. Thompson, J., Zamboni, W. C., Cheshire, P. J., Richmond, L. B., Luo, X., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of oral administration of irinotecan against neuroblastoma xenografts. Anti-Cancer Drugs, 8: 313-322, 1997.
23. Thompson, J., Zamboni, W. C., Chesire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997.
24. Chabot, G. G., Gouyette, A., and Bissery, M. C. Tumor influence on pharmacokinetics of the camptothecin analogue irinotecan (CPT-11) and active metabolite SN-38 in mice. Proc. Am. Assoc. Cancer Res., 35: 432, 1994.
25. Zamboni, W. C., Houghton, P. J., Thompson, J., Cheshire, P. J., Hanna, S., Richmond, L. B., Lou, X., and Stewart, C. F. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin. Cancer Res., in press, 1998.
26. Prueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O., and Vyas, K. P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in CACO-2 cells. Drug Metabolism Dispos., 24: 634-642, 1996.
27. Lund-Pero, M., Jeppson, B., Ameklo-Nobin, B., Sjogren, H-O., Holmgren, K., and Pero, R. W. Non-specific steroidal esterase activity and distribution in human and other mammalian tissues. Clin. Chim. Acta, 224: 9-20, 1994.
28. Jansen, W., Zwart, B., Hulscher, S., Giaccone, G., Pinedo, H., and Boven, E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer, 70: 335-340, 1997.
29. Houghton, P. J., Houghton, J. A., Myers, L., Cheshire, P. J., Howbert, J. J., and Grindey, G. B. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol., 25: 84-89, 1989.
30. Houghton, J. A., Cheshire, P. J., Hallman, J. D., Lutz, L., Luo, X., Li, Y., and Houghton, P. J. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin. Cancer Res., 2: 107-118, 1996.
31. Rivory, L. P., and Robert, J. Reversed-phase high-performance liquid Chromatographic method for the simultaneous quantification of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatogr. Biol. Biomed. Appl., 661: 133-141, 1994.
32. D'Argenio, D. Z., and Schumitzky, A. ADAPT II User's Guide, University of Southern California. Los Angeles: Biomedical Simulations Resource, 1990.
33. Stewart, C. F., Zamboni, W. C., Crom, W. R., and Houghton, P. J, Disposition of irinotecan and SN-38 following oral and intravenous dosing in mice. Cancer Chemother. Pharmacol., 40: 259-265, 1997.
34. Yeh, K. C., and Kwan, K. C. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J. Pharmacokinet. Biopharm., 6: 79-98, 1978.
35. Gibaldi, M., and Perrier, D. Pharmacokinetics. New York: Marcel Dekker, 1982.
36. Neter, J., Wasserman, W., and Kutner, M. H. Applied linear statistical models. New York: Irwin, 1990.
37. van Leeuwen, P. A. M., Drukker, J., van Der Kleyn, N. M., van Den Boogaard, A. E. J. M., and Soeters, P. B. Morphological effects of high dose neomycin sulfate on the small and large intestine. Acta Morphol. Neeri-Scand., 24: 223-234, 1986.
38. Chen, S. F., Rothenberg, M. L., Clark, G., Degen, D., Wajima, M., Barton, D., and Von Hoff, D. D. Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc. Am. Assoc. Cancer Res., 35: A2174, 1994.
39. Kanzawa, F., Kondoh, H., Kwon, S. J., and Saijo, N. Role of carboxylesterase on metabolism of camptothecin analog (CPT-11) in non-small cell lung cancer cell line PC-7 cells. Proc. Am. Assoc. Cancer Res., 33: 427, 1992.
40. Ogasawara, H., Nishio, K., Kanzawa, F., Lee, Y-S., Funayama, Y., Ohira, T., Kuraishi, Y., Isogai, Y., and Saijo, N. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn. J. Cancer Res., 86: 124-129, 1995.
41. Narita, M., Nagai, E., Hagiwara, H., Aburada, M., Yokoi, T., and Kamataki, T. Inhibition of β-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 23: 5-10, 1993.
42. - secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Arch. Pharmacol., 351: 309-314, 1995.